TREM2 Therapeutic Strategy Post-INVOKE-2
Based on the literature provided, I'll generate novel therapeutic hypotheses for TREM2 modulation in neurodegeneration:
These hypotheses integrate the emerging understanding that TREM2's role is highly context-dependent, requiring sophisticated therapeutic approaches that consider disease stage, tissue environment, and cellular phenotypes rather than simple agonism or antagonism.
Based on the literature provided, I'll generate novel therapeutic hypotheses for TREM2 modulation in neurodegeneration:
These hypotheses integrate the emerging understanding that TREM2's role is highly context-dependent, requiring sophisticated therapeutic approaches that consider disease stage, tissue environment, and cellular phenotypes rather than simple agonism or antagonism.
I'll provide a rigorous critique of each TREM2 therapeutic hypothesis, identifying weaknesses and gaps in the evidence.
Counter-evidence: Multiple Aβ clearance therapies have shown limited clinical efficacy despite mechanistic success, questioning the clearance paradigm.
Falsification experiments:
- Test sequential agonist→antagonist treatment in transgenic models
- Measure receptor desensitization and rebound inflammation
- Compare outcomes to continuous single-strategy approaches
Revised confidence: 0.4 (down from 0.8)
Counter-evidence: DAM with high TREM2 expression are found around plaques and may contribute to pathology rather than protection.
Falsification experiments:
- Generate microglia-specific TREM2 overexpression mice
- Test in chronic neurodegeneration models (not acute inflammation)
- Compare resident vs total microglial TREM2 modulation
Revised confidence: 0.3 (down from 0.7)
Falsification experiments:
- Test U1 snRNA brain delivery and microglial uptake
- Measure functional TREM2 protein levels after splicing correction
- Test in multiple genetic TREM2 variant backgrounds
Revised confidence: 0.45 (down from 0.75)
Counter-evidence: TREM2 deficiency in humans causes early-onset dementia, suggesting essential protective functions.
Falsification experiments:
- Test TREM2 antagonists in chronic neurodegeneration models
- Measure overall microglial health and essential functions
- Compare brain vs peripheral tissue fibrosis mechanisms
Revised confidence: 0.25 (down from 0.6)
Falsification experiments:
- Test TREM2 modulation effects on brain T-cell infiltration
- Measure autoimmune markers and neuroinflammation
- Compare cancer vs neurodegeneration TREM2+ cell functions
Revised confidence: 0.2 (down from 0.5)
Falsification experiments:
- Directly measure microglial metabolism after TREM2 modulation
- Test functional consequences of metabolic reprogramming
- Compare metabolic vs direct anti-inflammatory approaches
Revised confidence: 0.3 (down from 0.65)
Falsification experiments:
- Develop and test region-specific delivery methods
- Map regional TREM2 function requirements across disease progression
- Test regional vs systemic treatment approaches
Revised confidence: 0.15 (down from 0.55)
The hypotheses suffer from several common critical flaws:
1. Over-extrapolation from limited peripheral tissue data to complex brain environments
2. Mechanistic gaps between proposed interventions and desired outcomes
3. Insufficient consideration of TREM2's essential homeostatic functions
4. Technology assumptions about deliverability and specificity that remain unproven
5. Oversimplified models of microglial function and neurodegeneration mechanisms
Key missing experiments across all hypotheses:
- Direct testing in relevant chronic neurodegeneration models
- Comprehensive safety assessment of TREM2 modulation approaches
- Validation of proposed delivery and targeting mechanisms
- Comparison with existing therapeutic approaches
The most promising aspects involve Hypothesis 3 (genetic precision medicine) due to its mechanistic foundation, though still limited in scope.
I'll provide a rigorous critique of each TREM2 therapeutic hypothesis, identifying weaknesses and gaps in the evidence.
Counter-evidence: Multiple Aβ clearance therapies have shown limited clinical efficacy despite mechanistic success, questioning the clearance paradigm.
Falsification experiments:
- Test sequential agonist→antagonist treatment in transgenic models
- Measure receptor desensitization and rebound inflammation
- Compare outcomes to continuous single-strategy approaches
Revised confidence: 0.4 (down from 0.8)
Counter-evidence: DAM with high TREM2 expression are found around plaques and may contribute to pathology rather than protection.
Falsification experiments:
- Generate microglia-specific TREM2 overexpression mice
- Test in chronic neurodegeneration models (not acute inflammation)
- Compare resident vs total microglial TREM2 modulation
Revised confidence: 0.3 (down from 0.7)
Falsification experiments:
- Test U1 snRNA brain delivery and microglial uptake
- Measure functional TREM2 protein levels after splicing correction
- Test in multiple genetic TREM2 variant backgrounds
Revised confidence: 0.45 (down from 0.75)
Counter-evidence: TREM2 deficiency in humans causes early-onset dementia, suggesting essential protective functions.
Falsification experiments:
- Test TREM2 antagonists in chronic neurodegeneration models
- Measure overall microglial health and essential functions
- Compare brain vs peripheral tissue fibrosis mechanisms
Revised confidence: 0.25 (down from 0.6)
Falsification experiments:
- Test TREM2 modulation effects on brain T-cell infiltration
- Measure autoimmune markers and neuroinflammation
- Compare cancer vs neurodegeneration TREM2+ cell functions
Revised confidence: 0.2 (down from 0.5)
Falsification experiments:
- Directly measure microglial metabolism after TREM2 modulation
- Test functional consequences of metabolic reprogramming
- Compare metabolic vs direct anti-inflammatory approaches
Revised confidence: 0.3 (down from 0.65)
Falsification experiments:
- Develop and test region-specific delivery methods
- Map regional TREM2 function requirements across disease progression
- Test regional vs systemic treatment approaches
Revised confidence: 0.15 (down from 0.55)
The hypotheses suffer from several common critical flaws:
1. Over-extrapolation from limited peripheral tissue data to complex brain environments
2. Mechanistic gaps between proposed interventions and desired outcomes
3. Insufficient consideration of TREM2's essential homeostatic functions
4. Technology assumptions about deliverability and specificity that remain unproven
5. Oversimplified models of microglial function and neurodegeneration mechanisms
Key missing experiments across all hypotheses:
- Direct testing in relevant chronic neurodegeneration models
- Comprehensive safety assessment of TREM2 modulation approaches
- Validation of proposed delivery and targeting mechanisms
- Comparison with existing therapeutic approaches
The most promising aspects involve Hypothesis 3 (genetic precision medicine) due to its mechanistic foundation, though still limited in scope.
Competitive Landscape:
- Alector leads TREM2 agonism (AL002, AL003)
- Genentech developing TREM2 modulators
- Multiple companies developing Alzheimer's biomarkers for staging
Cost & Timeline:
- Discovery to IND: 4-5 years ($40-60M)
- Phase I/II: 5-6 years ($100-150M)
- Phase III: 4-5 years ($400-600M)
- Total: 13-16 years, $540-810M
Safety Concerns:
- Major risk: Sequential drug switching could cause rebound inflammation
- Biomarker dependence: Misclassification could lead to wrong treatment
- Regulatory complexity: FDA may require separate approvals for each stage
Druggability Assessment:
- Target: TREM2-metabolic pathway interface poorly defined
- Challenge: Indirect metabolic effects difficult to predict and control
Existing Compounds/Clinical Matter:
- No specific TREM2-metabolic modulators in development
- General metabolic modulators (metformin, NAD+ boosters) in neurodegeneration trials
- Requires extensive mechanism-of-action studies
Cost & Timeline:
- Target validation: 2-3 years ($15-25M)
- Discovery to IND: 5-6 years ($50-80M)
- Clinical development: 8-10 years ($300-500M)
- Total: 15-19 years, $365-605M
Safety Concerns:
- Unknown metabolic consequences of chronic TREM2 modulation
- Systemic effects on peripheral metabolism
- Drug-drug interactions with metabolic medications
Highest Priority: Hypothesis 3 (Splicing-based rescue) - leverages established ASO platform, clear patient population, manageable regulatory path.
Conditional Development: Hypothesis 1 (Stage-dependent) - only if robust biomarker companion diagnostics are developed first.
Deprioritize: Hypotheses 2, 4, 5, 6, 7 - insufficient mechanistic foundation and/or technically infeasible with current technology.
The field needs foundational biomarker development before sophisticated TREM2 modulation strategies become clinically viable. Current anti-neuroinflammatory approaches should focus on validated targets with clear patient stratification strategies.
Competitive Landscape:
- Alector leads TREM2 agonism (AL002, AL003)
- Genentech developing TREM2 modulators
- Multiple companies developing Alzheimer's biomarkers for staging
Cost & Timeline:
- Discovery to IND: 4-5 years ($40-60M)
- Phase I/II: 5-6 years ($100-150M)
- Phase III: 4-5 years ($400-600M)
- Total: 13-16 years, $540-810M
Safety Concerns:
- Major risk: Sequential drug switching could cause rebound inflammation
- Biomarker dependence: Misclassification could lead to wrong treatment
- Regulatory complexity: FDA may require separate approvals for each stage
Druggability Assessment:
- Target: TREM2-metabolic pathway interface poorly defined
- Challenge: Indirect metabolic effects difficult to predict and control
Existing Compounds/Clinical Matter:
- No specific TREM2-metabolic modulators in development
- General metabolic modulators (metformin, NAD+ boosters) in neurodegeneration trials
- Requires extensive mechanism-of-action studies
Cost & Timeline:
- Target validation: 2-3 years ($15-25M)
- Discovery to IND: 5-6 years ($50-80M)
- Clinical development: 8-10 years ($300-500M)
- Total: 15-19 years, $365-605M
Safety Concerns:
- Unknown metabolic consequences of chronic TREM2 modulation
- Systemic effects on peripheral metabolism
- Drug-drug interactions with metabolic medications
Highest Priority: Hypothesis 3 (Splicing-based rescue) - leverages established ASO platform, clear patient population, manageable regulatory path.
Conditional Development: Hypothesis 1 (Stage-dependent) - only if robust biomarker companion diagnostics are developed first.
Deprioritize: Hypotheses 2, 4, 5, 6, 7 - insufficient mechanistic foundation and/or technically infeasible with current technology.
The field needs foundational biomarker development before sophisticated TREM2 modulation strategies become clinically viable. Current anti-neuroinflammatory approaches should focus on validated targets with clear patient stratification strategies.
```json
{
"ranked_hypotheses": [
{
"title": "Splicing-Based TREM2 Rescue Therapy",
"description": "Modified U1 snRNA therapy to correct TREM2 splicing defects in patients with partial loss-of-function mutations, restoring functional protein levels through precision medicine approach for genetic TREM2 variants.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.8,
"evidence_strength": 0.7,
"novelty": 0.9,
"feasibility": 0.7,
"therapeutic_potential": 0.7,
"druggability": 0.8,
"safety_profile": 0.7,
"competitive_landscape": 0.8,
"data_availability": 0.6,
"reproducibility": 0.7
},
"composite_score": 0.74
},
{
"title": "Stage-Dependent TREM2 Modulation Strategy",
"description": "TREM2 agonism in early neurodegeneration for enhanced microglial Aβ clearance, followed by controlled antagonism in late stages to prevent excessive tissue damage, leveraging temporal therapeutic switching.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.6,
"evidence_strength": 0.5,
"novelty": 0.8,
"feasibility": 0.4,
"therapeutic_potential": 0.7,
"druggability": 0.6,
"safety_profile": 0.3,
"competitive_landscape": 0.5,
"data_availability": 0.7,
"reproducibility": 0.4
},
"composite_score": 0.56
},
{
"title": "Metabolic Reprogramming Through TREM2 Modulation",
"description": "TREM2 antagonism to metabolically reprogram microglia from pro-inflammatory glycolytic state to anti-inflammatory oxidative metabolism, reducing neuroinflammation while maintaining essential functions.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.4,
"evidence_strength": 0.3,
"novelty": 0.8,
"feasibility": 0.3,
"therapeutic_potential": 0.6,
"druggability": 0.4,
"safety_profile": 0.4,
"competitive_landscape": 0.7,
"data_availability": 0.4,
"reproducibility": 0.3
},
"composite_score": 0.46
},
{
"title": "Cardiac-Inspired Neuroprotective TREM2hi Strategy",
"description": "Inducing TREM2hi resident microglial phenotype similar to protective cardiac macrophages to maintain neuronal homeostasis during neuroinflammation, mimicking cardiomyocyte-protective mechanisms.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.4,
"evidence_strength": 0.3,
"novelty": 0.7,
"feasibility": 0.3,
"therapeutic_potential": 0.5,
"druggability": 0.5,
"safety_profile": 0.4,
"competitive_landscape": 0.6,
"data_availability": 0.5,
"reproducibility": 0.3
},
"composite_score": 0.45
},
{
"title": "Tissue-Specific TREM2 Targeting Strategy",
"description": "Region-specific TREM2 modulation based on local microglial phenotypes and disease progression patterns, using targeted delivery systems to optimize outcomes while minimizing systemic effects.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.3,
"evidence_strength": 0.2,
"novelty": 0.9,
"feasibility": 0.2,
"therapeutic_potential": 0.6,
"druggability": 0.2,
"safety_profile": 0.4,
"competitive_landscape": 0.8,
"data_availability": 0.3,
"reproducibility": 0.2
},
"composite_score": 0.39
},
{
"title": "Anti-Fibrotic TREM2 Antagonism for Chronic Neuroinflammation",
"description": "TREM2 antagonists to prevent microglial-mediated tissue fibrosis and scarring in chronic neurodegenerative diseases by promoting apoptosis of pro-fibrotic microglia and targeting pathological survival signals.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.3,
"evidence_strength": 0.2,
"novelty": 0.7,
"feasibility": 0.3,
"therapeutic_potential": 0.4,
"druggability": 0.5,
"safety_profile": 0.2,
"competitive_landscape": 0.7,
"data_availability": 0.4,
"reproducibility": 0.2
},
"composite_score": 0.39
},
{
"title": "Immune Checkpoint Modulation via TREM2",
"description": "Selective TREM2 modulation to enhance adaptive immunity against protein aggregates by targeting TREM2+ microglial suppression of T-cell responses while preserving homeostatic functions.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.2,
"evidence_strength": 0.2,
"novelty": 0.8,
"feasibility": 0.2,
"therapeutic_potential": 0.4,
"druggability": 0.4,
"safety_profile": 0.2,
"competitive_landscape": 0.6,
"data_availability": 0.3,
"reproducibility": 0.2
},
"composite_score": 0.35
}
],
"knowledge_edges": [
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "microglial_activation",
"target_type": "biological_process",
"relation": "regulates"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "amyloid_clearance",
"target_type": "biological_process",
"relation": "enhances"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "neuroinflammation",
"target_type": "biological_process",
"relation": "modulates"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "Alzheimer_disease",
"target_type": "disease",
"relation": "risk_factor"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "splicing_machinery",
"target_type": "molecular_complex",
"relation": "regulated_by"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "DAP12_signaling",
"target_type": "pathway",
"relation": "activates"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "metabolic_reprogramming",
"target_type": "biological_process",
"relation": "influences"
},
{
"source_id": "U1_snRNA",
"source_type": "therapeutic",
"target_id": "TREM2",
"target_type": "gene",
"relation": "modifies_splicing"
},
{
"source_id": "AL002",
"source_type": "therapeutic",
"target_id": "TREM2",
"target_type": "gene",
"relation": "agonizes"
},
{
"source_id": "disease_stage",
"source_type": "clinical_parameter",
"target_id": "TREM2_modulation_strategy",
"target_type": "therapeutic_approach",
"relation": "determines"
}
],
"synthesis_summary": "The synthesis reveals a critical need for precision in TREM2-targeted therapeutic development, with the splicing-based rescue therapy emerging as the most viable near-term approach due to its strong mechanistic foundation, established delivery platforms (ASOs), and clear patient stratification strategy. The stage-dependent modulation strategy, while conceptually appealing, faces significant challenges in biomarker development, safety validation, and regulatory complexity that currently limit its feasibility. The remaining hypotheses suffer from fundamental gaps in mechanistic understanding, technological limitations, or safety concerns that prevent clinical translation with current knowledge and capabilities.\n\nThe knowledge graph analysis illuminates TREM2's central role as a regulatory hub connecting microglial activation, neuroinflammation, and neurodegeneration, but also highlights the complexity of context-dependent functions that make therapeutic targeting challenging. Critical knowledge gaps include the temporal dynamics of TREM2 function across disease progression, tissue-specific requirements for different brain regions, and the long-term consequences of sustained TREM2 modulation. Future therapeutic development should prioritize biomarker discovery for patient stratification, safety validation in chronic treatment models, and mechanistic studies to understand TREM2's dual protective and pathological roles before advancing complex multi-stage or metabolic reprogramming approaches."
}
```
```json
{
"ranked_hypotheses": [
{
"title": "Splicing-Based TREM2 Rescue Therapy",
"description": "Modified U1 snRNA therapy to correct TREM2 splicing defects in patients with partial loss-of-function mutations, restoring functional protein levels through precision medicine approach for genetic TREM2 variants.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.8,
"evidence_strength": 0.7,
"novelty": 0.9,
"feasibility": 0.7,
"therapeutic_potential": 0.7,
"druggability": 0.8,
"safety_profile": 0.7,
"competitive_landscape": 0.8,
"data_availability": 0.6,
"reproducibility": 0.7
},
"composite_score": 0.74
},
{
"title": "Stage-Dependent TREM2 Modulation Strategy",
"description": "TREM2 agonism in early neurodegeneration for enhanced microglial Aβ clearance, followed by controlled antagonism in late stages to prevent excessive tissue damage, leveraging temporal therapeutic switching.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.6,
"evidence_strength": 0.5,
"novelty": 0.8,
"feasibility": 0.4,
"therapeutic_potential": 0.7,
"druggability": 0.6,
"safety_profile": 0.3,
"competitive_landscape": 0.5,
"data_availability": 0.7,
"reproducibility": 0.4
},
"composite_score": 0.56
},
{
"title": "Metabolic Reprogramming Through TREM2 Modulation",
"description": "TREM2 antagonism to metabolically reprogram microglia from pro-inflammatory glycolytic state to anti-inflammatory oxidative metabolism, reducing neuroinflammation while maintaining essential functions.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.4,
"evidence_strength": 0.3,
"novelty": 0.8,
"feasibility": 0.3,
"therapeutic_potential": 0.6,
"druggability": 0.4,
"safety_profile": 0.4,
"competitive_landscape": 0.7,
"data_availability": 0.4,
"reproducibility": 0.3
},
"composite_score": 0.46
},
{
"title": "Cardiac-Inspired Neuroprotective TREM2hi Strategy",
"description": "Inducing TREM2hi resident microglial phenotype similar to protective cardiac macrophages to maintain neuronal homeostasis during neuroinflammation, mimicking cardiomyocyte-protective mechanisms.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.4,
"evidence_strength": 0.3,
"novelty": 0.7,
"feasibility": 0.3,
"therapeutic_potential": 0.5,
"druggability": 0.5,
"safety_profile": 0.4,
"competitive_landscape": 0.6,
"data_availability": 0.5,
"reproducibility": 0.3
},
"composite_score": 0.45
},
{
"title": "Tissue-Specific TREM2 Targeting Strategy",
"description": "Region-specific TREM2 modulation based on local microglial phenotypes and disease progression patterns, using targeted delivery systems to optimize outcomes while minimizing systemic effects.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.3,
"evidence_strength": 0.2,
"novelty": 0.9,
"feasibility": 0.2,
"therapeutic_potential": 0.6,
"druggability": 0.2,
"safety_profile": 0.4,
"competitive_landscape": 0.8,
"data_availability": 0.3,
"reproducibility": 0.2
},
"composite_score": 0.39
},
{
"title": "Anti-Fibrotic TREM2 Antagonism for Chronic Neuroinflammation",
"description": "TREM2 antagonists to prevent microglial-mediated tissue fibrosis and scarring in chronic neurodegenerative diseases by promoting apoptosis of pro-fibrotic microglia and targeting pathological survival signals.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.3,
"evidence_strength": 0.2,
"novelty": 0.7,
"feasibility": 0.3,
"therapeutic_potential": 0.4,
"druggability": 0.5,
"safety_profile": 0.2,
"competitive_landscape": 0.7,
"data_availability": 0.4,
"reproducibility": 0.2
},
"composite_score": 0.39
},
{
"title": "Immune Checkpoint Modulation via TREM2",
"description": "Selective TREM2 modulation to enhance adaptive immunity against protein aggregates by targeting TREM2+ microglial suppression of T-cell responses while preserving homeostatic functions.",
"target_gene": "TREM2",
"dimension_scores": {
"mechanistic_plausibility": 0.2,
"evidence_strength": 0.2,
"novelty": 0.8,
"feasibility": 0.2,
"therapeutic_potential": 0.4,
"druggability": 0.4,
"safety_profile": 0.2,
"competitive_landscape": 0.6,
"data_availability": 0.3,
"reproducibility": 0.2
},
"composite_score": 0.35
}
],
"knowledge_edges": [
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "microglial_activation",
"target_type": "biological_process",
"relation": "regulates"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "amyloid_clearance",
"target_type": "biological_process",
"relation": "enhances"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "neuroinflammation",
"target_type": "biological_process",
"relation": "modulates"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "Alzheimer_disease",
"target_type": "disease",
"relation": "risk_factor"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "splicing_machinery",
"target_type": "molecular_complex",
"relation": "regulated_by"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "DAP12_signaling",
"target_type": "pathway",
"relation": "activates"
},
{
"source_id": "TREM2",
"source_type": "gene",
"target_id": "metabolic_reprogramming",
"target_type": "biological_process",
"relation": "influences"
},
{
"source_id": "U1_snRNA",
"source_type": "therapeutic",
"target_id": "TREM2",
"target_type": "gene",
"relation": "modifies_splicing"
},
{
"source_id": "AL002",
"source_type": "therapeutic",
"target_id": "TREM2",
"target_type": "gene",
"relation": "agonizes"
},
{
"source_id": "disease_stage",
"source_type": "clinical_parameter",
"target_id": "TREM2_modulation_strategy",
"target_type": "therapeutic_approach",
"relation": "determines"
}
],
"synthesis_summary": "The synthesis reveals a critical need for precision in TREM2-targeted therapeutic development, with the splicing-based rescue therapy emerging as the most viable near-term approach due to its strong mechanistic foundation, established delivery platforms (ASOs), and clear patient stratification strategy. The stage-dependent modulation strategy, while conceptually appealing, faces significant challenges in biomarker development, safety validation, and regulatory complexity that currently limit its feasibility. The remaining hypotheses suffer from fundamental gaps in mechanistic understanding, technological limitations, or safety concerns that prevent clinical translation with current knowledge and capabilities.\n\nThe knowledge graph analysis illuminates TREM2's central role as a regulatory hub connecting microglial activation, neuroinflammation, and neurodegeneration, but also highlights the complexity of context-dependent functions that make therapeutic targeting challenging. Critical knowledge gaps include the temporal dynamics of TREM2 function across disease progression, tissue-specific requirements for different brain regions, and the long-term consequences of sustained TREM2 modulation. Future therapeutic development should prioritize biomarker discovery for patient stratification, safety validation in chronic treatment models, and mechanistic studies to understand TREM2's dual protective and pathological roles before advancing complex multi-stage or metabolic reprogramming approaches."
}
```